The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.
 
Badi Edmond El Osta
No Relationships to Disclose
 
Madhusmita Behera
No Relationships to Disclose
 
Sungjin Kim
No Relationships to Disclose
 
Lynne D Berry
No Relationships to Disclose
 
Gabriel Sica
No Relationships to Disclose
 
Rathi Narayana Pillai
Consulting or Advisory Role - Natera
Travel, Accommodations, Expenses - Clovis Oncology; Genentech/Roche; Novartis; Takeda
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Eisai; G1 Therapeutics; Genentech/Roche; Lilly; Novartis; Sandoz; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Genentech/Roche
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)
 
Bruce E. Johnson
Stock and Other Ownership Interests - KEW
Honoraria - Chugai Pharma; Merck
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis Oncology; Genentech; KEW; Lilly; Merck; Novartis; Transgene
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute
Expert Testimony - Genentech
 
David J. Kwiatkowski
No Relationships to Disclose
 
Paul A. Bunn
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Lilly; Merck; Merck Serono; Merrimack; Novartis; Pfizer; Puma Biotechnology
 
Fadlo Raja Khuri
No Relationships to Disclose
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer